1. Management of NTM Lung Disease

3. Overview of NTM Lung Disease

4. Overview of NTM Lung Disease (cont)

5. Incidence and Prevalence of NTM Lung Disease Oregon

6. Importance of Early Identification Diagnosis

7. ATS/IDSA Diagnostic Criteria

8. Susceptibility Testing, Slow-Growing M. Kansasii

9. Susceptibility Testing Slow-Growing: MAC

10. Susceptibility Testing Fast-Growing: M. Abscessus

11. NTM Lung Disease Complementary Approaches

12. Which Patients Require Antibiotic Therapy?

13. Cavitary vs Noncavitary NTM Lung Disease

14. Treatment of Macrolide-Susceptible NTM Lung Disease

15. Treatment for M Abscessus

16. Treatment for M Kansasii

17. Limitations of Standard Care

18. Treatment-Related AEs

19. ALIS Overview

20. Phase 3 CONVERT Trial

21. CONVERT Findings

22. Adverse Events

23. ALIS as a New Agent in the NTM Treatment Armamentarium

24. Clofazimine Overview

25. Clofazimine Observational Cohort Study

26. Clofazimine Safety

27. Bedaquiline Overview

28. Bedaquiline Findings

29. Oxazolidinones Tedizolid, Linezolid

30. Concluding Remarks

31. Abbreviations

32. Abbreviations (cont)